|
Company* (Country; Symbol) |
Funding Institution |
Amount (M) |
Type# |
Details (Date) |
|
| ||||
Acacia Research Corp. (CBMX) |
Department of Defense |
$5.9 |
Contract award |
Acacia's Combimatrix Group was awarded the contract to develop microarray technology for detectting biological threat agents (3/8) |
|
|
|
|
|
Adenosine Therapeutics LLC* |
National Institutes of Health |
$0.101 |
Phase I SBIR grant |
To fund identification of novel agonists of A2A adenosine receptors that are orally active and longer acting (12/2) |
|
|
|
|
|
Adenosine Therapeutics LLC* |
Department of Defense |
$0.198 |
Phase I SBIR grant |
To fund research to develop A2A adenosine receptor agonists as adjuncts to antibiotics for treatment of anthrax septicemia (10/30) |
|
|
|
|
|
Aeres Biomedical Ltd.* (UK) |
National Cancer Institute |
ND |
Contract award |
The NCI awarded Aeres a contract to design, construct and express a humanized antibody against CD-22, for non-Hodgkin's lymphoma (1/21**) |
|
|
|
|
|
AdipoGenix Inc.* |
National Institutes of Health |
ND |
Phase I SBIR grant |
AdipoGenix said it got a grant to discover drugs for obesity, and a grant to develop assays to identify compounds that increase fatty acid metabolism (11/17) |
|
|
|
|
|
Adventrx Pharmaceuticals Inc. (OTC BB:AVRX) |
National Institutes of Health |
$1.3 |
Grant |
The M.D. Anderson Cancer Center got the grant to further develop Adventrx's EradicAide vaccine technology for HIV/AIDS (2/20) |
|
|
|
|
|
Agencourt Bioscience Corp.* |
National Human Genome Research Institute |
$27.2 |
Grant |
Agencourt was awarded the money over three years as one of five centers to undertake large-scale genome sequencing projects for priority organisms designated by the NIH (11/7) |
|
|
|
|
|
Affitech AS* (Norway) |
National Functional Genomics program (Norway) |
NOK6.2 (US$0.881) |
Grant |
Affitech and the Norwegian Radium Hospital got the grant to continue research on new cancer therapeutics, vaccines and diagnostics (2/18**) |
|
|
|
|
|
Altor BioScience Corp.* |
National Cancer Institute |
$0.1 |
SBIR grant |
The one-year grant will support development of soluble T-cell antigen receptor reagents for tumor diagnostic applications (3/29) |
|
|
|
|
|
Affymetrix Inc. (AFFX) |
National Human Genome Research Institute |
ND |
Research grant |
To support Affymetrix and academic researchers in applying GeneChip technology to the Encodeproject, the next phase of the Human Genome Project (10/22) |
|
|
|
|
|
Aphios Corp.* |
National Institute of Allergy and Infectious Diseases |
ND |
Phase I SBIR grant |
The grant will support developments of HIV drugs from Aphios' library of marine microorganisms (3/23) |
|
|
|
|
|
AusAm Biotechnologies Inc.* |
National Institutes of Health |
ND |
Contract grant |
To support development of DES10, a topical microbicide, as a prophylactic ointment against HIV and other STDs (2/24) |
|
|
|
|
|
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
National Institute of Allergy and Infectious Diseases |
$0.75 |
Grant |
The grant follows an initial SBIR award for further development of fully human antibodies to anthrax toxins using Avanir's Xenerex technology (3/2) |
|
|
|
|
|
Biofrontera Pharmaceuticals GmbH* (Germany) |
North Rhine Westphalia state government (Germany) |
€4 (US$5) |
Technology and Innovation Program grant |
To support discovery of drug candidates for treating chronic pain and Parkinson's disease (2/18) |
|
|
|
|
|
BioPort Corp.* |
Department of Defense |
$29.7 |
Manufacturing contract |
BioPort was awarded a contract for producing an anthrax vaccine; BioPort will get at least $29.7M and could get up to $245M, depending on the number of doses ordered (1/9) |
|
|
|
|
|
BioSante Pharmaceuticals Inc. (AMEX:BPA) |
Department of Defense (via Dynport Vaccine Co. Ltd.) |
$0.658 |
Joint Vaccine Acquisition Program subcontract |
BioSante got a subcontract to develop alternative routes of administration for anthrax vaccines (1/7) |
|
|
|
|
|
|
|
|
|
|
BioXell SpA* (Italy) |
Italian Research Ministry |
€7.3 (US$8.9) |
Research grant and loan |
The money will support research into treatments for inflammatory diseases; two-thirds of the funds are repayable over 10 years (3/11) |
|
|
|
|
|
Blue Heron Biotechnology Inc.* |
National Human Genome Research Institute |
$0.143 |
Phase I SBIR grant |
To improve Blue Heron's gene synthesis platform, GeneMaker, by reducing the error frequency in synthetic DNA (10/28) |
|
|
|
|
|
Cerus Corp. (CERS) |
ND |
ND |
SBIR grant |
Grant is related to development of the cancer antigen mesothelin (1/28) |
|
|
|
|
|
Chimerix Inc.* |
National Institute of Allergy and Infectious Diseases |
$0.6 |
Phase I SBIR grant |
Two-year grant will support pre-clinical development of drugs for treating multidrug-resistant HIV-1 infection (3/11) |
|
|
|
|
|
Coley Pharmaceutical Group Inc.* |
National Institute Of Allergy and Infectious Diseases |
$5.8 |
BioDefense Partnerships program grant |
To support research and development of immunostimulatory CpG TLR9 agonists as inhalable agents to protect against bioterror agents (10/21) |
|
|
|
|
|
Commonwealth Biotechnologies Inc. (CBTE) |
The Department of the Army |
ND |
Subcontract |
The company will analyze mail from the Pentagon's mail-sorting center for particular pathogens and toxins (3/24) |
|
|
|
|
|
Commonwealth Biotechnologies Inc. (CBTE) |
Unnamed federal agencies and private companies |
$1 |
Contract awards |
One deal is for identification of agents in swabs taken from mail facilities, and the other is for analysis of environmental samples for bioagents (3/9) |
|
|
|
|
|
Corixa Corp. (CRXA) |
National Institute of Allergy and Infectious Diseases |
$11.6 |
Contract award |
Corixa got a five-year contract to develop its molecules that act on the TLR4 receptor and may offer immunity to infectious agents (1/5) |
|
|
|
|
|
Crucell NV (the Netherlands; CRXL) |
National Institute of Allergy and Infectious Diseases |
$3.5 |
Support agreement |
The NIAID will provide up to $3.5M to cover preclinical costs of Crucell's AdVac-based malaria vaccine (3/30) |
|
|
|
|
|
Curacyte AG* (Germany) |
German state of Thuringia |
€1.2 (US$1.4) |
Corporate Technology Development Program grant |
The company's Curacyte Chemistry GmbH subsidiary was given the grant to fund preclinical development of small-molecule inhibitors of Factor Xa (10/29) |
|
|
|
|
|
CytoGenix Inc. (OTC BB:CYGX) |
National Cancer Institute |
ND |
Research grant |
To fund testing of an aerosol compound containing a single- stranded DNA expression vector coded with an anticancer gene sequence on mice with induced metastatic lung tumors (3/10) |
|
|
|
|
|
Cytomatrix LLC (U.S. subsidiary of CordLife; Singapore) |
Department of Defense |
$1.7 |
Contract award |
Deal to use Cytomatrix's T-cell production technology to screen vaccine prototypes under development (1/18) |
|
|
|
|
|
DeCode Genetics Inc. (Iceland; DCGN) |
The Simons Foundation |
$2.8 |
Grant |
DeCode got a grant for a population-based study of the genetics of autism and autism spectrum disorders (1/7) |
|
|
|
|
|
Devgen NV (Belgium) |
Flemish government |
€1.9M (US$2.2M) |
Promotion of scientific and technological research grant |
To support work at Devgen using C. elegans-based technology to identify the mechanism of action of drugs (11/20) |
|
|
|
|
|
Direvo Biotech AG* (Germany) |
State government of North Rhine- Westphalia (Germany) |
€3.9M (US$4.9) |
Grant |
Four-year grant to support development of a technology platform for the generation of novel therapeutic proteins (1/14) |
|
|
|
|
|
Diversa Corp. (DVSA) |
Deparment of Defense |
$2.28 |
Award from the DOD's Chemical and Biological Defense Initiatives Fund |
Diversa will work with Agentase LLC and Life Science Research Israel Ltd. to develop an enzyme- based system capable of decontaminating chemical and biological warfare agents (1/8) |
|
|
|
|
|
Encore Pharmaceuticals Inc.* |
National Institutes of Health |
$0.1 |
Phase I SBIR grant |
To further work by Encore and Oklahoma Medical Research Foundation scientists to identify natural products and molecules for use in neurological diseases (10/30) |
|
|
|
|
|
Epimmune Inc. (EPMN) |
National Cancer Institute |
$0.6 |
Phase I grant |
Two-year grant will support pre- clinical work on a multi-epitope vaccine for ovarian and breast cancer; University of Washington researchers are collaborating on the project (3/31) |
|
|
|
|
|
FeRx Inc.* |
National Cancer Institute |
$0.1 |
Phase I SBIR grant |
To evaluate use of FeRx's Magne-Targ for the delivery of gemcitabine in treating pancreatic cancer (10/28) |
|
|
|
|
|
Galapagos Genomics NV* (Belgium) |
Flemish government |
€1.4 (US$1.8) |
Flemish Institute for Promotion of Industrial Scientific- technological Research grant |
Galapagos will build Alzheimer's disease-relevant assays using neuronal cells and will use them with its adenoviral-based target discovery platform (2/12) |
|
|
|
|
|
Generex Biotechnology Corp. (GNBT) |
Department of Defense |
$0.525 |
DOD Concept Award |
Generex's Antigen Express unit will further develop its vaccine technology in prostate cancer; the basis is suppressing expression of the immunoregulatory Ii protein (1/30) |
|
|
|
|
|
Genomatica Inc.* |
National Human Genome Research Institute |
$0.765 |
Phase II SBIR grant |
The two-year grant will support a program to integrate high-throughput experimental data with its computer models of cellular metabolism (11/4) |
|
|
|
|
|
GenVec Inc. (GNVC) |
U.S. Naval Medical Research Center |
ND |
Collaborative Research and Development Agreement |
NMRC will provide GenVec optimized malaria genes to be used in adenovector vaccines being developed by GenVec and PATH's Malaria Vaccine Initiative (3/31) |
|
|
|
|
|
GenVec Inc. (GNVC) |
PATH's Malaria Vaccine Initiative |
$2.5 |
Collaborative research, development and supply agreement |
GenVec will produce and evaluate adenovirus vectors containing genes for up to five malaria antigens (3/31) |
|
|
|
|
|
GenVec Inc. (GNVC) |
National Institute of Allergy and Infectious Diseases (via SAIC-rederick Inc.) |
$1.3 |
Subcontract with the NIAID's Vaccine Research Center |
Expanded subcontract calls for $1.3M in potential additional funding, for nearly $30M total; GenVec will manufacture adenovector SARS vaccine for early clinical testing (2/25) |
|
|
|
|
|
GenVec Inc. (GNVC) |
National Institute of Allergy and Infectious Diseases (via SAIC-rederick Inc.) |
$12 |
Subcontract with the NIAID's Vaccine Research Center |
Expanded subcontract calls for $12M in potential additional funding, for a total of $28M; GenVec will manufacture adenovector HIV vaccine for late-stage clinical development (1/6) |
|
|
|
|
|
GenVec Inc. (GNVC) |
National Eye Institute |
$0.2 |
SBIR grants |
Two awards to enhance research using pigment epithelium-derived factor for treating eye diseases (12/9) |
|
|
|
|
|
Hawaii Biotech Inc.* |
National Institute of Allergy and Infectious Diseases |
$5.6 |
Phase II SBIR grant (from Small Business Biodefense Program) |
The focus is on optimizing compounds to inhibit the toxin secreted by anthrax bacteria (2/17) |
|
|
|
|
|
HMGene Inc.* |
National Institutes of Health |
$0.739 |
Phase II SBIR grant |
The two-year grant will support work to identify and validate drug targets for obesity using HMGene's Adiposense technology (12/16) |
|
|
|
|
|
HGT Inc.* |
National Cancer Institute |
$0.5 |
Grant |
Two-year grant for HTG to identify and validate sets of genes for toxicity studies and develop a new array product (3/16) |
|
|
|
|
|
Ingenium Pharmaceuticals AG* (Germany) |
Europe |
€11.7 (US$14.5) |
European Community Sixth Framework grant |
Ingenium, the University of Cambridge and a number of institutions are part of a consortium to discover genetic targets in obesity (1/8) |
|
|
|
|
|
Isis Pharmaceuticals Inc. (ISIS) |
Defense Advanced Research Projects Agency |
$19.5 |
Contract |
Isis' Ibis program got a two-year contract to further develop its Tiger biosensor to identify infectious agents in biological warfare attacks (3/2) |
|
|
|
|
|
Lipid Sciences Inc. (LIPD) |
National Institutes of Health |
$0.1 |
STTR grant |
The one-year grant will fund work using delipidation technology to develop a preventive vaccine against SARS (3/25) |
|
|
|
|
|
Lynx Therapeutics Inc. (LYNX) |
National Institutes of Health (via SAIC-Frederick Inc.) |
ND |
Services agreement |
Lynx will characterize gene expression patterns in tissues from the mouse to build a reference transcriptome database; it said it was a multimillion-dollar deal (2/26) |
|
|
|
|
|
MacroPore Biosurgery Inc. (FSE:XMP) |
National Institutes of Health |
ND |
Phase I/II SBIR grant |
MacroPore will study the role of adipose-derived regenerative cells in treating myocardial infarction; the work will be done with researchers at UCLA (1/15) |
|
|
|
|
|
Merrimack Pharmaceuticals Inc.* |
National Cancer Institute |
ND |
Phase I SBIR grant |
The grant supports development of antibodies using yeast display technology for use in microarrays, for applications in cancer and autoimmune diseases (3/25) |
|
|
|
|
|
Merrimack Pharmaceuticals Inc.* |
National Cancer Institute |
ND |
Phase I SBIR grant |
The grant supports development of Merrimack's microarray-based Network Biology platform in apoptosis and cancer (1/29) |
|
|
|
|
|
Microbiotix Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
Phase II SBIR grant |
Two-year grant to support development of MBX-300 for treating respiratory syncytial virus infections (3/18) |
|
|
|
|
|
MycoLogics Inc.* |
Department of Health and Human Services |
ND |
Phase I SBIR grant |
MycoLogics will work with the California Institute for Medical Research to develop a vaccine against Aspergillus fumigatus, a fungus that causes multiple diseases (3/15) |
|
|
|
|
|
MycoLogics Inc.* |
Department of Health and Human Services |
ND |
Phase I SBIR grant |
MycoLogics will work to isolate a new class of compounds to treat fungal disease by disrupting beta(1,6)-glucan synthesis (3/1) |
|
|
|
|
|
MycoLogics Inc.* |
Department of Health and Human Services |
ND |
Phase I SBIR grant |
Company will work to derive a novel vaccine against San Joaquin Valley fever (2/5) |
|
|
|
|
|
NanoBio Corp.* |
Department of Defense |
$3.2 |
Contract award |
NanoBio will use the award in the area of infectious diseases (12/16) |
|
|
|
|
|
NanoCure Corp.* |
Michigan Economic Development Corp. |
$0.187 |
Contract award |
NanoCure is getting $187,000 over three years to develop a drug delivery platform based on dendrimer technology (1/27) |
|
|
|
|
|
NaPro BioTherapeutics Inc. (NPRO) |
National Institute of Neurological Disorders and Stroke |
ND |
SBIR grant |
To use its gene editing techno- logy to address inherited mutations in animal models of Duchenne muscular dystrophy (12/4) |
|
|
|
|
|
Neurome Inc.* |
National Institutes of Health |
ND |
Phase I SBIR grant |
To develop better predictive test systems along with specific biological markers for drug target expression patterns; Neurome is working with PsychoGenics Inc. to develop the screening platforms (2/25) |
|
|
|
|
|
NewLink Geneitcs Inc.* |
Iowa Department of Economic Development |
$6 |
Iowa Values Fund Board award |
NewLink was among companies that received state-incentive funding; the money will support NewLink's work in cancer (2/19) |
|
|
|
|
|
NovaScreen Biosciences Corp. |
National Institute of Allergy and Infectious Diseases |
$12.95 |
Contract award |
The contract, "Innate Immune Receptors and Adjuvant Discovery," focuses on establishing a pipeline of drug candidates that stimulate the innate immune system (1/15) |
|
|
|
|
|
Oncosis LLC* |
National Science Foundation |
ND |
Phase II SBIR grant |
To further develop its method of cell loading, Laserfect, on the Laser-Enabled Analysis and Processing platform (11/13) |
|
|
|
|
|
Oragenics Inc. (OTC BB:OGEN) |
National Institute of Allergy and Infectious Diseases |
$0.1 |
Phase I SBIR grant |
The grant supports development of technology to identify genes of M. tuberculosis that are specifically induced during human infections (3/4) |
|
|
|
|
|
Origen Therapeutics Inc.* |
National Institute of Allergy and Infectious Diseases |
$0.34 |
Phase I SBIR grant |
The grant supports work on generating human polyclonal antibodies in chicken eggs for use as passive immunotherapy to combat pathogens and toxins (2/18) |
|
|
|
|
|
Oxford BioMedcia plc (UK; LSE:OXB) |
Department of Health (UK) |
£0.5 (US$0.915) |
Award |
The award will support development of LentiVector technology for use in treating single-gene inherited disorders, with a focus on hemophilia A (3/29) |
|
|
|
|
|
Ozgene Pty. Ltd.* (Australia) |
National Institute of Allergy and Infectious Diseases |
$8.5 |
Contract award |
Ozgene will supply genetically modified mice to institute researchers (3/3) |
|
|
|
|
|
Paratek Pharmaceuticals Inc.* |
Medicines for Malaria Venture |
ND |
Grant |
To support investigation of tetracycline derivatives that may be active against the malaria parasite Plasmodium falciparum (2/24) |
|
|
|
|
|
Peregrine Pharmaceuticals Inc. (PPHM) |
National Institute of Allergy and Infectious Diseases |
$1.68 |
Research grant |
Researchers at the University of Texas Southwestern Medical Center got the grant to study Peregrine antibodies against Lassa fever (11/3) |
|
|
|
|
|
Phytodyne Inc.* |
Iowa Department of Economic Development |
$5 |
Iowa Values Fund Board award |
Three-year award to support the company's work in agricultural biotechnology (2/19) |
|
|
|
|
|
Prana Biotechnology Ltd. (Australia; PRAN) |
Australian government |
A$1.35 (US$1.04) |
R&D Start grant |
To take Prana's candidate for Alzheimer's disease drug, PBT-2, through safety testing and Phase I clinical trials (2/18) |
|
|
|
|
|
Proneuron Biotechnologies Inc.* |
The Marcus Foundation |
$3.2 |
Financing commitment |
Proneuron and the Shepherd Center will use the money to establish a cell-processing center in Atlanta and support Shepherd's participation in Proneuron's Phase II study of ProCord for acute spinal cord injury (3/9) |
|
|
|
|
|
Proteome Sciences plc* (UK) |
European Commission |
€0.438 (US$0.544) |
Sixth Framework grant |
Proteome is participating in a three-year program in pharmacogenomics for prediction of therapeutic response to antidepressants (2/13) |
|
|
|
|
|
Proteome Sciences plc* (UK) |
UK goverment |
£0.419 (US$0.775) |
DTI-Link grant |
Proteome and King's College, London, will work to improve the early detection of Alzheimer's disease and to discover new targets for therapy (2/9) |
|
|
|
|
|
Ribonomics Inc.* |
North Carolina Biotechnology Center |
$0.15 |
Research grant |
The grant will be used to complete development of the Ribonomics Analysis System, a functional clustering technology (2/3) |
|
|
|
|
|
Solexa Ltd.* (UK) |
UK Department of Trade and Industry and the Medical Research Council |
£0.7 (US$1.26) |
LINK grant |
The grant supports a genomics effort by Solexa, the European Bioinformatics Institute, Imperial College London and Wellcome Trust Sanger Institute (3/2) |
|
|
|
|
|
Surromed Inc.* |
National Institutes of Health |
ND |
SBIR grant |
To support development of a modified version of recombinant human annexin V for cardiovascular indications (10/23) |
|
|
|
|
|
Vical Inc. (VICL) |
National Institute of Allergy and Infectious Diseases |
$1 |
Phase I SBIR grant and research grant |
The grants will support development of Vical's plasmid DNA vaccine against cytomegalovirus (3/8) |
|
|
|
|
|
Vical Inc. (VICL) |
National Institute of Allergy and Infectious Diseases |
$6 |
Subcontract awards from SAIC-Frederick Inc. |
Vical got the money awarded in a May 2003 contract from the NIAID's Vaccine Research Center for production of DNA vaccines (2/9) |
|
|
|
|
|
V.I. Technologies Inc. (VITX) |
National Heart, Lung and Blood Institute (NIH) |
$0.885 |
Phase I and II Fast Track grant |
Two-year grant related to Vitex's Inactine system for advancing the transfusion safety of blood (2/9) |
|
|
|
|
|
Xcellsyz Ltd.* (UK) |
Department of Trade and Industry (UK) |
£0.75 (US$1.26) |
Grant |
The grant will be used to test the company's cell-based approach to discovery through development of the XD4000 compound series (10/31) |
|
|
|
|
|
Zivena Inc.* |
State of Ohio |
$8 |
Research grant |
Zivena is part of a team that got a grant to develop Zivena's Resmycin (inhaled doxorubicin) for lung cancer; others are Ohio State University, Batelle Memorial Institute and Siemens; they also got $13.5M in financial commitment (11/11) |
|
|
|
|
|
|
| ||||
Notes: | ||||
* Indicates a privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
# SBIR = Small Business Innovation Research; STTR =Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | ||||
